Unresolved clinical aspects and safety hazards of blood derived- EV/MV in stored blood components: From personal memory lanes to newer perspectives on the roles of EV/MV in various biological phenomena

Transfusion and Apheresis Science

Volumn 55, Issue 1, 2016, Pages 10-22

  Seghatchian, Jerard ^a   Amiral, Jean ^b  

^a International Consultancy in Blood Components Quality Safety Improvement   (United Kingdom)

^b SYSMEX CORPORATION   (Japan)

Author keywords

Biomarkers; cell activity; disease state; Extracellular Vesicles; intercellular crosstalk

Indexed keywords

GROWTH FACTOR; LIPID; MEMBRANE RECEPTOR; MICRORNA; PHOSPHATIDYLSERINE; BIOLOGICAL MARKER;

APHERESIS; APOPTOSIS; BLOOD CLOTTING; BLOOD COMPONENT; BLOOD SAFETY; CELL VIABILITY; CENTRIFUGATION; COMPLEMENT ACTIVATION; ENDOTHELIUM CELL; ERYTHROCYTE; EXOSOME; HUMAN; INFLAMMATION; LEUKOCYTE; MEGAKARYOCYTE; PHOSPHOLIPID BILAYER; REVIEW; RISK ASSESSMENT; SHEAR STRESS; THROMBOCYTE; THROMBOCYTE PRESERVATION; THROMBOCYTOPENIA; BLOOD STORAGE; CYTOLOGY; METABOLISM; PROCEDURES;

BIOMARKERS; BLOOD PLATELETS; BLOOD PRESERVATION; BLOOD SAFETY; HUMANS;

EID: 84983565485     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2016.07.007     Document Type: Review

References (44)

1. [1] Seghatchian, J., The multifaceted aspects of blood cell-derived micro-particles: an intriguing aspect of my past subject of studies. Transfus Apher Sci 53 (2015), 103–105.
2. [2] Seghatchian, J., Burnouf, T., Blood cell-derived microvesicles with potential pathogenic roles in therapeutic blood components and specialized diagnostic tools in diseases. Transfus Apher Sci 53 (2015), 108–109.
3. [3] Poncelet, P., Robert, S., Bailly, N., Garnache-Ottou, F., Bouriche, T., Devalet, B., et al. Tips and tricks for flow cytometry-based analysis and counting of micro-particles. Transfus Apher Sci 53 (2015), 110–126.
4. [4] Amiral, J., Seghatchian, J., The diagnostic usefulness of captures assays for measuring global/ specific extracellular micro-particles in plasma. Transfus Apher Sci 53 (2015), 127–136.
5. [5] Burnouf, T., Chou, M.-L., Goubran, H., Cognasse, F., Garraud, O., Seghatchian, J., An overview of the role of micro-particles/microvesicles in blood components: are they clinically beneficial or harmful?. Transfus Apher Sci 53 (2015), 137–145.
6. [6] Prudent, M., Crettaz, D., Delobel, J., Seghatchian, J., Tissot, J.-D., Lion, N., Differences between calcium-stimulated and storage-induced erythrocyte-derived microvesicles. Transfus Apher Sci 53 (2015), 153–158.
7. [7] Johnson, L., Raynel, S., Seghatchian, J., Marks, D.C., Platelet micro-particles in cryopreserved platelets: potential mediators of haemostasis. Transfus Apher Sci 53 (2015), 146–152.
8. [8] Cognasse, F., Hamzeh-Cognasse, H., Laradi, S., Chou, M.-L., Seghatchian, J., Burnouf, T., Boulanger, C., et al. The role of micro-particles in inflammation and transfusion: a concise review. Transfus Apher Sci 53 (2015), 159–167.
9. [9] Goubran, H., Sabri, W., Kobt, R., Seghatchian, J., Burnouf, T., Platelet micro-particles and cancer: an intimate cross talk. Transfus Apher Sci 53 (2015), 168–172.
10. [10] Lin, H.-C., Chang, H.-W., Hsiao, S.-H., Chou, M.-L., Seghatchian, J., Burnouf, T., Platelet-derived micro-particles trigger THP-1 monocytic cell aggregation and release of pro-coagulant tissue factor-expressing micro-particles in vitro. Transfus Apher Sci 53 (2015), 246–252.
11. [11] Gardiner, C., Harrison, P., Belting, M., Böing, A., Campello, E., Carter, B.S., et al. Extracellular vesicles, tissue factor, cancer and thrombosis discussion themes of the ISEV 2014 Educational Day. J Extracell Vesicles, 4, 2015, 26901 http://dx.doi.org/10.3402/jev.v4.26901.
12. [12] Goubran, H.A., Burnouf, T., Stakiw, J., Seghatchian, J., Platelet micro-particles: a sensitive physiological” fine tuning” balancing factor in health and disease. Transfus Apher Sci 52:2 (2015), 12–18.
13. [13] Krailadsiri, P., Seghatchian, J., Amiral, J., Contreras, M., Annexin V, a new marker of platelet storage lesion: correlation with dMPV. Transfus Sci 18:2 (1997), 223–226.
14. [14] Seghatchian, J., A new platelet storage lesion index based on paired samples, without and with EDTA and cell counting: comparison of three types of leukoreduced preparations. Transfus Apher Sci 35 (2007), 283–292.
15. [15] Vasconcelos, E., Sousa, A.P., Seghatchian, J., de Sousa, G., The content of the LRS chamber provides a new quality tool for the characterization of the donor platelet profile. Transfus Apher Sci 32:2 (2005), 221–225.
16. [16] Krailadsiri, P., Seghatchian, J., Microvesicles in blood components: laboratory and clinical aspects. Art Bode Clin Appl Thromb Hem 3 (1997), 86–95.
17. [17] Bessos, H., Seghatchian, J., Cutts, M., Seghatchian, J., Cutts, M., Murphy, W.G., Glycoprotein-IB and glycoprotein-IIB/IIIA in the quality assessment of platelet concentrates during storage. Blood Coagul Fibrinolysis 3:5 (1992), 633–636.
18. [18] Seghatchian, J., A new approach to the determination of coagulation factors using chromogenic substrates. Med Lab Sci 35:4 (1978), 343–346.
19. [19] Salunkhe, V., van der Meer, P.F., de Korte, D., Seghatchian, J., Gutierrez, L., Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Apher Sci 52:2 (2015), 19–34.
20. [20] Prudent, M., D'Alessandro, A., Cazenave, J.P., Devine, D.V., Gachet, C., Greinacher, A., et al. Proteome changes in platelets after pathogen inactivation – an interlaboratory consensus. Transfus Med Rev 28 (2014), 72–83.
21. [21] Seghatchian, J., Highlights of the role of PMP in health & disease & advancements in PRT and quality in transfusion establishments. Transfus Apher Sci 52:2 (2015), 10–11.
22. [22] de Sousa, G., Seghatchian, J., Highlights of PBTI Coimbra conference on PRT of plasma& current opinions on pathogen reduction treatment of blood components. Transfus Apher Sci 52 (2015), 228–232.
23. [23] Seghatchian, J., Multilayer-strategy to enhance optimal safety of the blood supply: the role of pathogen inactivation for optimizing recipient safety and helping health care cost containment. Transfus Apher Sci 52 (2015), 233–236.
24. [24] Seghatchian, J., Putter, J.S., Advances in transfusion science for shock-trauma: optimising the clinical management of acute haemorrhage. Transfus Apher Sci 53 (2015), 412–422.
25. [25] Seghatchian, J., Universal leucodepletion: an overview of some unresolved issues and the highlights of lessons learned. Transfus Apher Sci 29:2 (2003), 105–117.
26. [26] Bianchi, M., Vaglio, S., Pupella, S., Marano, G., Facco, G., Liumbruno, G.M., et al. Leucoreduction of blood components: an effective way to increase blood safety?. Blood Transfus, 2015, 10.2450/2015.0154-15.
27. [27] Hervig, T., Seghatchian, J., Leukocyte-reduced blood components: laboratory and clinical aspects. Rossi's principles of transfusion medicine, 5th ed, 2016, W.BP Ltd Chapter 24; in press.
28. [28] Solheim, B.G., Seghatchian, J., Pathogen inactivation. Rossi's principles of transfusion medicine, 4th ed, 2009, W.BP Ltd., 801–810 Chapter 51.
29. [29] D'Alessandro, A., Dzieciatkowska, M., Hill, R.C., Hansen, K.C., Supernatant protein biomarkers of red blood cell storage hemolysis as determined through an absolute quantification proteomics technology. Transfusion, 2016 in press.
30. [30] Seghatchian, J., Watts, R.L., Watts, D.C., Rapid location of acetylcholinesterase and other esterases, after separation of enzyme components of solubilized 7 times washed red cell ghost free from Hb, on columns or by electrophoresis, by means of the fluorescent hydrolysis Products of substrate N-Methoxyl acetate. Biochemical Society Transaction. 537th meeting, Canterbury, 1973, 747–749.
31. [31] Krailadsiri, P., Seghatchian, J., Macgregor, I., Drummond, O., Perrin, R., Spring, F., et al. The effect of leukodepletion on the generation and removal of microvesicles and prion protein in bleed components. Transfusion 46 (2006), 407–447.
32. [32] Garraud, O., Cognasse, F., Tissot, J.D., Chavarin, P., Laperche, S., Morel, P., et al. Improving platelet transfusion safety: biomedical and technical considerations. Blood Transfus, 2016, 10.2450/2015.0042-15.
33. [33] Yingdi, Z., Liang, Q., Michel, P., Bondarenko, A., Gasilova, N., Beggah, S., et al. Sensitive and fast identification of bacteria in blood samples by immunoaffinity mass spectrometry for quick BSI diagnosis. Chem Sci, 7(5), 2016 https://www.researchgate.net/publication/292076228 The Royal Society of Chemistry.
34. [34] D'Alessandro, A., Kriebardis, A.G., Rinalducci, S., Antonelou, M.H., Hansen, K.C., Papassideri, I.S., et al. An update on red blood cell storage lesions, as gleaned through biochemistry and omics technologies. Transfusion 55 (2015), 205–219.
35. [35] Bruce, L.J., Anstee, D.J., Unconventional cell death in erythroid cells. Blood, 127, 2016, 10.1182/blood-2015-11-677229.
36. [36] Laffont, B., Corduan, A., Rousseau, M., Duchez, A.-C., Lee, C.H.C., Boilard, E., et al. Platelet micro-particles reprogram macrophage gene expression and function. Thromb Haemost 115 (2016), 311–323.
37. [37] Silliman, C.C., Moore, E.E., Kelher, M.R., Khan, S.Y., Gellar, L., Elzi, D.J., Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury. Transfusion 51 (2011), 2549–2554.
38. [38] Dzieciatkowska, M., Silliman, C.C., Moore, E.E., Kelher, M.R., Banerjee, A., Land, K.J., et al. Proteomic analysis of the supernatant of red blood cell units: the effects of storage and leucoreduction. Vox Sang 105 (2013), 210–218.
39. [39] Anniss, A.M., Glenister, K.M., Killian, J.J., Sparrow, R.L., Proteomic analysis of supernatants of stored red blood cell products. Transfusion 45 (2005), 1426–1433.
40. [40] Gyulkhandanyan, A.V., Mutlu, A., Freedman, J., Leytin, V., Markers of platelet apoptosis: methodology and applications. J Thromb Thrombolysis 33:4 (2012), 397–411.
41. [41] Loötvall, J., Hill, A.F., Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles, 3, 2014, 26913 http://dx.doi.org/10.3402/jev.v3.26913.
42. [42] Yáñez-Mo, M., Siljander, P.R., Andreu, Z., Zavec, A.B., Borràs, F.E., Buzas, E.I., et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles, 4, 2015, 27066 http://dx.doi.org/10.3402/jev.v4.27066.
43. [43] Kooijmans, S.A.A., Fliervoet, L.A.L., Van der Meel, R., Fens, M.H.A.M., Heijnen, H.F.G., van Bergen en Henegouwen, P.M.P., et al. Pegylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. J Control Release, 2016, 10.1016/j.jconrel.2016.01.009.
44. [44] Flaumenhaft, R., Dilks, J., Richardson, J., Alden, E., Patel-Hett, S.R., Battinelli, E., et al. Megakaryocyte-derived micro-particles: direct visualization and distinction from platelet-derived micro-particles. Blood 113:5 (2008), 1112–1121.